What is HC Wainwright’s Estimate for CMPS Q1 Earnings?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – HC Wainwright issued their Q1 2027 EPS estimates for Compass Pathways in a research report issued on Wednesday, March 25th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($0.42) per share for the quarter. HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Compass Pathways’ Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.18) EPS and Q4 2027 earnings at ($0.08) EPS.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Tuesday, March 24th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.20).

CMPS has been the topic of several other research reports. Compass Point set a $15.00 price objective on Compass Pathways in a research note on Thursday, February 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research note on Wednesday, January 21st. Canaccord Genuity Group increased their price target on Compass Pathways from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Royal Bank Of Canada raised their price target on Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Finally, Lifesci Capital upgraded Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $21.88.

Compass Pathways Price Performance

Shares of CMPS stock opened at $5.62 on Thursday. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55. Compass Pathways has a 12-month low of $2.25 and a 12-month high of $8.90. The firm has a fifty day moving average of $6.74 and a 200-day moving average of $6.30. The firm has a market capitalization of $539.63 million, a price-to-earnings ratio of -1.82 and a beta of 1.90.

Hedge Funds Weigh In On Compass Pathways

A number of large investors have recently added to or reduced their stakes in the company. RTW Investments LP increased its holdings in Compass Pathways by 0.6% during the 4th quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock worth $60,426,000 after purchasing an additional 50,000 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after purchasing an additional 1,350,698 shares in the last quarter. Millennium Management LLC boosted its position in shares of Compass Pathways by 39.9% during the third quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock worth $15,562,000 after buying an additional 774,090 shares during the period. Toronto Dominion Bank boosted its position in shares of Compass Pathways by 152.9% during the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock worth $17,447,000 after buying an additional 1,529,013 shares during the period. Finally, ARK Investment Management LLC grew its holdings in shares of Compass Pathways by 1.6% during the fourth quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock worth $14,876,000 after buying an additional 34,894 shares in the last quarter. Institutional investors own 46.19% of the company’s stock.

Key Compass Pathways News

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: Morgan Stanley kept an Overweight rating on CMPS while trimming its price target to $16 (from $18). The new target implies roughly a 185% upside from the current price level, which can attract buyers and support upward momentum. Benzinga
• Neutral Sentiment: Company released its fourth-quarter and full-year 2025 results and business highlights via BusinessWire; management emphasized the progress of COMP360 and broader development milestones. The release provides context for results and pipeline progress but did not override the EPS miss. BusinessWire
• Neutral Sentiment: Multiple short-interest reports for March show data anomalies (reported totals of “0 shares” and NaN changes). The reported days-to-cover/short-interest ratio reads as 0.0, which is likely a reporting error rather than a real change in short positioning. Investors should treat these figures cautiously until corrected filings are available. (Sources aggregated)
• Negative Sentiment: Q4 EPS missed consensus: CMPS reported a loss per share of ($0.59) vs. the expected ($0.39), missing by $0.20. An EPS miss typically pressures biotech names, as it raises questions about near-term financial performance and cash runway. Press Release

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.